Literature DB >> 8360929

Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.

T J Smith1, B E Hillner, C E Desch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8360929     DOI： 10.1093/jnci/85.18.1460

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  17 in total

Review 1.  Evaluating the public health impact of health promotion interventions: the RE-AIM framework.

Authors:  R E Glasgow; T M Vogt; S M Boles
Journal:  Am J Public Health       Date:  1999-09       Impact factor: 9.308

2.  Economic analysis of randomized, controlled trials.

Authors:  G H Lyman
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

3.  Fair and effective resource allocation in cancer care: uncharted territory?

Authors:  J A Green; C Williams; A Cribb; B Brecher; M Evans
Journal:  Health Care Anal       Date:  1996-02

Review 4.  Prognosis without treatment as a modifier in health economic assessments.

Authors:  Ross Camidge; Andrew Walker; James J Oliver; Fiona Nussey; Simon Maxwell; Duncan Jodrell; David J Webb
Journal:  BMJ       Date:  2005-06-11

Review 5.  The effectiveness of cost-effectiveness analysis in containing costs.

Authors:  N A Azimi; H G Welch
Journal:  J Gen Intern Med       Date:  1998-10       Impact factor: 5.128

6.  Genetic tests: a search for economy of scale.

Authors:  B Hillner
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

Review 7.  Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.

Authors:  F Wisløff; N Gulbrandsen; E Nord
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

8.  A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.

Authors:  R Launois; J Reboul-Marty; B Henry; J Bonneterre
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

9.  Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.

Authors:  E Nord; F Wisløff; M Hjorth; J Westin
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

10.  Management and costs of treating lung cancer patients in a university hospital.

Authors:  Konstantin J Dedes; Thomas D Szucs; Stephan Bodis; Markus Joerger; Adam Lowy; Erich W Russi; Hans C Steinert; Walter Weder; Rolf A Stahel
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.